New research suggests the blockbuster weight-loss drugs may carry a hidden cost — one that could redefine how doctors weigh the risks and rewards of long-term use.
GLP-1 receptor agonists — the class of drugs reshaping conversations about obesity, diabetes, and even heart disease — may be carrying a side effect that has largely flown under…
